Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Prognosis of Patients With Sepsis After Immunotherapy
Sponsor: Sun Yat-sen University
Summary
Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year mortality) of patients with sepsis after immunotherapy. Based on the preliminary clinical study (NCT02867267), this study will conduct long-term follow-up for sepsis patients to provide data support for the long-term prognosis of immunotherapy.
Official title: Long-term Prognosis After Thymosin Alpha 1 Treatment in Patients With Sepsis: A Multicenter Cohort Study
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
900
Start Date
2021-07-01
Completion Date
2027-03-31
Last Updated
2021-05-25
Healthy Volunteers
No
Interventions
Thymosin Alpha1
Drug interventions have been done in previous clinical studies